Dendreon

Dendreon is hiring Regional Business Directors and Key Account Managers to support continued access to PROVENGE® (sipuleucel T) across key U.S. markets. Key Account Manager locations include: • Birmingham • Philadelphia • Upstate New York • Seattle / Portland • Chicago Regional Business Director positions are available for the following regions: • Northeast • Southeast • West • Central These roles are focused on helping bring PROVENGE to more patients with metastatic castration‑resistant prostate cancer (mCRPC). Why these roles matter: • Partner strategically with urology and oncology providers • Play a key role in how personalized immunotherapy is integrated into evolving treatment pathways • Make a meaningful impact for patients through science‑driven solutions At Dendreon, you’ll join a collaborative, mission‑driven team committed to innovation and improving outcomes for patients and providers alike. If you’re passionate about advancing prostate cancer care and ready to make an impact, we’d love to connect. Explore open roles and apply: https://brnw.ch/21x23wA #Dendreon #Hiring #BiotechCareers #Oncology #Pharma #SalesCareers #Immunotherapy #ProstateCancer

We are thrilled to share that Dendreon will be part of the AUA Annual Meeting in Washington, DC! #AUA2026 brings together urologists from around the world to explore the latest research, new guidelines, and advancements in urologic care. Visit us at Exhibit #3851 to connect with our team. We look forward to seeing you there!

In advanced prostate cancer, understanding disease progression depends on consistent, timely insight. Dr. Benjamin H. Lowentritt highlights how regular screening plays a critical role in helping clinicians identify changes early and better assess how the disease is evolving over time. Watch now: https://brnw.ch/21x1Yg7 #ProstateCancer #mCRPC #Imaging

Immunotherapy can be part of the treatment discussion for metastatic castration‑resistant prostate cancer (mCRPC), but it can raise unique questions and challenges. What’s your biggest challenge when discussing immunotherapy with mCRPC patients? #ProstateCancer #Immunotherapy #mCRPC

With over two decades of experience in personalized cellular immunotherapy, our work focuses on helping eligible patients with advanced prostate cancer access innovative treatment options. From clinical development to commercialization, every step is guided by our commitment to improving patient outcomes. Learn more about our approach: https://brnw.ch/21x1NdT #PatientFirst #Dendreon #Immunotherapy

Age is an important factor in prostate cancer. 6 in 10 diagnoses occur in men aged 65 or older, making age one of the primary risk factors for the disease. Understanding the data helps inform conversations about screening and early detection. Learn more about prostate cancer statistic: https://brnw.ch/21x1EWR #ProstateCancer #MensHealth

We were pleased to welcome Representative Lucy McBath (GA-6), along with leaders from Georgia Life Sciences and the Biotechnology Innovation Organization (BIO), to Dendreon’s immunotherapy manufacturing facility in Union City, Georgia. Led by Site Operations Director Veronica Marshall, the visit provided a firsthand look at the precision and complexity behind manufacturing personalized cancer immunotherapy. Rep. McBath—a two-time breast cancer survivor—was moved by the process, noting: “And these patients have no idea you do all this!” As a member of the House Committee on Education and the Workforce, Rep. McBath engaged with our Union City team—many of whom have grown their careers at Dendreon over the past decade—highlighting the importance of a highly skilled biomanufacturing workforce. The discussion also underscored the need to strengthen domestic biomanufacturing and advance policies that support continued growth in the U.S. life sciences sector. Dendreon is proud to support nearly 150 high-tech, highly skilled jobs in the Union City community as we continue advancing personalized cancer immunotherapy for patients.

Facing metastatic prostate cancer, Tom opens up about his diagnosis, his treatment choices, and the conversations with his healthcare team that shaped his path forward. ▶️ Hear his experience in his own words: https://brnw.ch/21x1rO4 #ProstateCancer #PatientStory #Dendreon

This #WorldHealthDay, our commitment remains clear: advancing cellular immunotherapy to help patients facing life-threatening diseases. Through personalized science and innovation, we're working to bring hope and meaningful treatment options to those who need them most. #Immunotherapy #CellularTherapy

From Urology Times: Drs. Alicia Morgans, MD, MPH, and Paul Sieber, MD, highlight recent advances in the therapeutic landscape, including the expanded use of germline and somatic genetic testing, microsatellite instability (MSI) assessment, and PSMA-PET imaging, which are refining treatment decision-making. In Episode 6, they explore how these innovations have expanded access to targeted agents and how physicians are incorporating individualized care strategies beyond guideline-defined pathways. Watch now: https://brnw.ch/21x1lWs